What in the World Happened With Bausch Health Stock Last Week?

Bausch Health stock surged 26% after Q3 results, following a raised outlook and a first $1B EBITDA quarter. Here is what drove the rally and what could slow it next.

Key Points
  • Bausch Health stock rose about 26% after Q3 results delivered its first $1 billion adjusted EBITDA quarter, higher cash flow, and a second guidance raise this year.
  • Xifaxan drives the growth, but a lower Medicare price starting Jan. 1, 2027, and normalizing inventory will weigh on the fourth quarter and 2027.
  • Falling debt, with net debt down more than $1 billion this year, is the real story to watch for long-term investors.

Few Canadian stocks have a past as colourful as Bausch Health (TSX: BHC). Many investors still remember it as Valeant, the drugmaker that renamed itself in 2018 and has spent years chipping away at a mountain of debt.

Last week, that story took a sharp turn. Shares of Bausch Health jumped over 25% following its Q3 results. Valued at a market cap of $4.2 billion, the TSX stock is still down 96% from all-time highs.

Is the Canadian healthcare stock finally a good buy right now?

chart reflected in eyeglass lenses

Source: Getty Images

Why did Bausch Health stock jump 26% after Q3 earnings?

Excluding its Bausch + Lomb eye care unit, Bausch Health posted revenue of $1.6 billion, up 12% from a year ago, in Q3.

It reported an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $1 billion. CEO Thomas Appio said it was the first time the company topped $1 billion in EBITDA in a single quarter.

Adjusted cash flow from operations rose $192 million to $539 million. Management used the excess cash to cut net debt by $521 million in the quarter and by more than $1 billion so far this year.

For the second time in 2026, the company raised its full-year targets. Revenue is now projected between $5.525 billion and $5.625 billion while adjusted EBITDA should land between $3.225 billion and $3.275 billion. Both figures exclude Bausch + Lomb, per the company’s press release.

Bausch Health runs five segments, from stomach and liver health to dermatology, aesthetics, and eye care.

Think of Salix as the key revenue driver as sales rose 16% to $831 million, the 17th consecutive quarter of growth. Another star performer was Xifaxan, a gut health drug, which grew 16% on higher net pricing and steady demand.

International revenue reached $299 million, and CFO J.J. Charhon noted that every segment grew revenue and segment profit.

However, organic revenue at Solta Medical, the aesthetics unit, slipped 4%. Management also admitted that Xifaxan volume got a lift from extra inventory in the sales channel.

How Bausch Health is shrinking its debt pile

Bausch Health ended Q3 with $2 billion in cash, and it plans to redeem its 2027 notes early to buy back up to $100 million of its public debt. It also announced a $50 million share buyback, mainly to offset dilution from management stock awards.

The adjusted EBITDA margin has widened by about 740 basis points since 2023.

Appio credited discipline for the performance, stating:

We have greater discipline, accountability, and consistency in our execution across the organization. The result is 14 consecutive quarters of revenue and Adjusted EBITDA growth across a diverse portfolio of businesses and markets.

What could slow Bausch Health stock in the fourth quarter?

Starting January 1, 2027, Medicare will pay a lower negotiated price for Xifaxan, which will trim Q4 revenue growth by eight percentage points and adjusted EBITDA growth by about 14 points.

Inventory at wholesalers and pharmacies should return to normal, which could shave off at least three more points of revenue growth.

Charhon put the net Medicare impact at roughly $400 million to $500 million year over year in 2027. Moreover, legal issues around Xifaxan could impact revenue and profit margins over the next 12 months.

A 26% pop does not erase a heavy debt load or a looming price cut on its top drug. However, it does show the turnaround is positively impacting cash flow.

Investors need to watch three things: Xifaxan prescriptions after the Medicare change, the pace of debt repayment, and new deals in hepatology, dermatology, and neuroscience.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »